Jefferies Initiates Coverage On Kinnate Biopharma with Buy Rating, Announces Price Target of $46
Jefferies analyst Roger Song initiates coverage on Kinnate Biopharma (NASDAQ:KNTE) with a Buy rating and announces Price Target of $46.
Stifel Initiates Coverage On Kinnate Biopharma with Buy Rating, Announces Price Target of $32
Stifel analyst Ben Burnett initiates coverage on Kinnate Biopharma (NASDAQ:KNTE) with a Buy rating and announces Price Target of $32.
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen’s Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 19)
Stocks That Hit 52-Week Lows On Thursday
Thursday morning, 173 companies reached new 52-week lows.
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios’ Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 17)
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 16)
Kinnate Biopharma Q2 EPS $(0.49) Up From $(2.05) YoY
Kinnate Biopharma (NASDAQ:KNTE) reported quarterly losses of $(0.49) per share. This is a 76.1 percent increase over losses of $(2.05) per share from the same period last year.
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 5)